Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.
Aclaris Therapeutics Inc (NASDAQ: ACRS) is a clinical-stage biopharmaceutical leader focused on pioneering therapies for immuno-inflammatory and dermatologic diseases. This page serves as the definitive source for verified news and press releases related to ACRS's research advancements, strategic partnerships, and operational developments.
Investors and industry professionals will find timely updates on clinical trial progress, regulatory milestones, and financial announcements. The curated collection includes updates on novel drug candidates like kinase inhibitors and antibody therapies targeting conditions with significant unmet medical needs.
All content is organized to provide clear insights into ACRS's dual-segment operations – from therapeutic innovations to contract research services. Regular updates ensure stakeholders stay informed about licensing agreements, pipeline expansions, and scientific breakthroughs without promotional bias.
Bookmark this page for streamlined access to essential Aclaris Therapeutics updates. Check back frequently for authoritative reporting on developments impacting both clinical research and investment considerations in the biopharmaceutical sector.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that Dr. Neal Walker, President and CEO, will present at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 1:00 p.m. ET. This presentation will provide an overview of the company's efforts in developing innovative drug candidates for immuno-inflammatory diseases. Aclaris' management will also be available for virtual one-on-one meetings throughout June 1st. The presentation can be viewed live on Aclaris' website, and the archive will be accessible for 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) reported Q1 2021 results with a net loss of $28.8 million, up from $15.6 million in Q1 2020. Total revenue increased to $1.8 million from $1.4 million. The company holds $142.7 million in cash and equivalents, sufficient to fund operations through 2023. Aclaris is advancing its drug pipeline with a Phase 2b trial for ATI-450 in rheumatoid arthritis and two additional trials for hidradenitis suppurativa and psoriatic arthritis. Results from the Phase 2a trial of ATI-1777 for atopic dermatitis are expected in Q2 2021.
Aclaris Therapeutics (NASDAQ: ACRS) has completed enrollment in its Phase 2a clinical trial of ATI-1777, a topical JAK 1/3 inhibitor for treating moderate to severe atopic dermatitis. The trial, which is randomized and double-blind, aims to assess the drug's efficacy and safety. Results are anticipated by mid-2021. This milestone follows positive preliminary results from another trial of ATI-450 for rheumatoid arthritis. Aclaris continues to develop treatments targeting immuno-inflammatory diseases and aims to demonstrate ATI-1777's potential while minimizing systemic exposure.
Aclaris Therapeutics (NASDAQ: ACRS) announced promising preliminary topline data for ATI-450, an oral MK2 inhibitor, from its Phase 2a trial in moderate to severe rheumatoid arthritis. This investigational drug showed significant clinical activity with sustained reductions in DAS28-CRP scores and enhanced inflammatory biomarker suppression over 12 weeks. For Q4 2020, Aclaris reported a net loss of $13.2 million, a decrease from $18.6 million in Q4 2019, along with total revenues of $1.6 million. Following a public offering in January 2021, Aclaris secured $103.5 million to strengthen its balance sheet.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that Dr. Neal Walker, President and CEO, will present at two upcoming virtual investor conferences. The presentations include the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET, and the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 10:00 a.m. ET. Management will also be available for virtual one-on-one meetings on both days. Webcasts of the presentations can be accessed on Aclaris' website and will be archived for 30 days.
Aclaris Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 25, 2021. Management will engage in a virtual fireside chat at 8:00 a.m. ET and will be available for one-on-one meetings throughout the day. Investors can access a live audio webcast of the chat on the company's website, which will be archived for 30 days. Aclaris focuses on developing innovative drug candidates for immuno-inflammatory diseases, leveraging a strong R&D pipeline.
Aclaris Therapeutics (Nasdaq:ACRS) has priced its underwritten public offering of 5,483,714 shares at $17.50 each, targeting gross proceeds of approximately $96 million. The offering includes a 30-day option for underwriters to purchase an additional 822,557 shares. Expected to close on or about January 22, 2021, this capital raise, facilitated by Cantor Fitzgerald & Co. and William Blair & Company, aims to support Aclaris' ongoing clinical-stage development in immuno-inflammatory diseases.
Aclaris Therapeutics (Nasdaq: ACRS) announced its intention to conduct an underwritten public offering of its common stock, subject to market conditions. The offering will include a 30-day option for underwriters to purchase an additional 15% of the shares. Cantor Fitzgerald & Co. and William Blair & Company are joint book-running managers for the offering. A shelf registration statement for these shares was filed with and declared effective by the SEC. The offering will be made via a prospectus supplement and will not constitute an offer without proper registration.
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced promising topline results from a 12-week, Phase 2a trial of ATI-450, an investigational oral MK2 inhibitor, for rheumatoid arthritis. The study showed durable clinical activity, with a significant 2.0 reduction in DAS28-CRP scores and 40% of treatment subjects achieving low disease activity by week 12. ATI-450 was generally well tolerated, with no serious adverse events reported. The company plans to advance ATI-450 to Phase 2b trials and publish full data analysis in a scientific journal.
Aclaris Therapeutics (ACRS) announced the establishment of a new Scientific Advisory Board comprising leading experts in immuno-inflammatory diseases. The board includes Drs. Stanley Cohen, Marco Colonna, James Krueger, and Michael Weinblatt, who bring extensive experience in rheumatology and immunology. Additionally, Aclaris expects preliminary topline data from the ATI-450-RA-201 Phase 2a trial for rheumatoid arthritis in January 2021. This development aims to enhance Aclaris’ R&D efforts in addressing unmet medical needs in immuno-inflammatory conditions.
